Literature DB >> 10980262

Ribavirin-induced resistance to heat shock, inhibition of the Ras-Raf-1 pathway and arrest in G(1).

S Vallée1, F Fouchier, D Braguer, J Marvaldi, S Champion.   

Abstract

Ribavirin [1-(beta-D-ribofuranosyl)1,2,4-triazole-3-carboxamide (virazole)], a specific inhibitor of inositide 5'-monophosphate dehydrogenase (IMPDH), induces a strong depletion of GTP pools in IGR39 cells. After a 3-day treatment, the cell cycle was reversibly arrested in G(0)/G(1), suggesting the involvement of GTP in the cell cycle process. The reduction of the GTP cell content modified the appearance of the microtubule network, as examined using immunofluorescence. However, the dynamics of repolymerisation were not altered. When arrested in G(0)/G(1), cells displayed a surprising resistance to a 3-h period of heat shock at 45 degrees C. Considering the lack of coimmunoprecipitation of p21ras with Raf-1, the reduction of the level of GTP-associated p21ras and the decrease of the activation of the extracellular signal-regulated protein kinases (ERK), also known as mitogen-activated protein (MAP) kinase, in ribavirin-treated cells, we suggest a possible relationship between the expression of heat-shock proteins and the change, in GTP-depleted cells, of the regulation of Raf kinase by ras protein.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10980262     DOI: 10.1016/s0014-2999(00)00596-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Down-regulation of multiple low dose streptozotocin-induced diabetes by mycophenolate mofetil.

Authors:  D Maksimovic-Ivanic; V Trajkovic; D J Miljkovic; M Mostarica Stojkovic; S Stosic-Grujicic
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

2.  Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.

Authors:  F Volpin; J Casaos; J Sesen; A Mangraviti; J Choi; N Gorelick; J Frikeche; T Lott; R Felder; S J Scotland; T S K Eisinger-Mathason; H Brem; B Tyler; N Skuli
Journal:  Oncogene       Date:  2016-12-12       Impact factor: 9.867

3.  Mycophenolic acid inhibits activation of inducible nitric oxide synthase in rodent fibroblasts.

Authors:  Dj Miljkovic; I Cvetkovic; S Stosic-Grujicic; V Trajkovic
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

4.  Efficacy of ribavirin against malignant glioma cell lines.

Authors:  Akiyoshi Ogino; Emiko Sano; Yushi Ochiai; Shun Yamamuro; Shinya Tashiro; Kazunari Yachi; Takashi Ohta; Takao Fukushima; Yutaka Okamoto; Kouhei Tsumoto; Takuya Ueda; Atsuo Yoshino; Yoichi Katayama
Journal:  Oncol Lett       Date:  2014-09-26       Impact factor: 2.967

5.  Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia.

Authors:  Karen A Urtishak; Li-San Wang; Biljana Culjkovic-Kraljacic; Katherine L B Borden; Carolyn A Felix; James W Davenport; Patrizia Porazzi; Tiffaney L Vincent; David T Teachey; Sarah K Tasian; Jonni S Moore; Alix E Seif; Shenghao Jin; Jeffrey S Barrett; Blaine W Robinson; I-Ming L Chen; Richard C Harvey; Martin P Carroll; Andrew J Carroll; Nyla A Heerema; Meenakshi Devidas; ZoAnn E Dreyer; Joanne M Hilden; Stephen P Hunger; Cheryl L Willman
Journal:  Oncogene       Date:  2018-11-26       Impact factor: 9.867

6.  Low-dose ribavirin treatments attenuate neuroinflammatory activation of BV-2 Cells by interfering with inducible nitric oxide synthase.

Authors:  Iva Bozic; Danijela Savic; Marija Jovanovic; Ivana Bjelobaba; Danijela Laketa; Nadezda Nedeljkovic; Mirjana Stojiljkovic; Sanja Pekovic; Irena Lavrnja
Journal:  Anal Cell Pathol (Amst)       Date:  2015-08-27       Impact factor: 2.916

7.  Ribavirin as a potential therapeutic for atypical teratoid/rhabdoid tumors.

Authors:  Betty Tyler; Nicolas Skuli; Joshua Casaos; Sakibul Huq; Tarik Lott; Raphael Felder; John Choi; Noah Gorelick; Michael Peters; Yuanxuan Xia; Russell Maxwell; Tianna Zhao; Chenchen Ji; Thomas Simon; Julie Sesen; Sarah J Scotland; Richard E Kast; Jeffrey Rubens; Eric Raabe; Charles G Eberhart; Eric M Jackson; Henry Brem
Journal:  Oncotarget       Date:  2018-01-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.